Sun Pharma and Cassiopea, a subsidiary of Cosmo Pharmaceuticals N.V. Introduced the signing of addendums to the License and Supply Agreements for WINLEVI (clascoterone) cream 1% increasing the territory to consist of Japan, Australia, New Zealand, Brazil, Mexico and Russia. In 2021, Sun Pharma and Cassiopea had signed License and Supply Agreements for the United States and Canada markets. Sun Pharma released WINLEVI inside the US market in November 2021.

Under the phrases of the above referred agreements, Sun Pharma will receive from Cassiopea the distinctive right to increase and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia. Cosmo will be the unique provider of the product. Cassiopea will get hold of an in advance charge of US$ 7 million, ability regulatory and income milestones and normal doubledigit royalties on internet sales.